KB-1223-01

Sacituzumab

Background

Trop2 is a type I cell surface glycoprotein, which is limited in normal tissues but highly expressed in human tumor tissues. Overexpression of TROP2 can promote the growth, proliferation and metastasis of tumor cells. This differentiated expression of TROP2 protein makes it a new target for researchers to develop antibody-coupled drugs. Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer.

Specifications

Catalog Number:
KB-1223-01
Cell Line Name:
Sacituzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
TROP2
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Hope S Rugo , Aditya Bardia , Sara M Tolaney , Carlos Arteaga , Javier Cortes , Joohyuk Sohn , Frederik Marmé , Quan Hong , Rosemary J Delaney , Amir Hafeez , Fabrice André , Peter Schmid . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.Future Oncol. 2020 Apr;16(12):705-715. 2.Aditya Bardia , Sara A Hurvitz , Sara M Tolaney , Delphine Loirat , Kevin Punie , Mafalda Oliveira , Adam Brufsky , Sagar D Sardesai , Kevin Kalinsky , Amelia B Zelnak , Robert Weaver , Tiffany Traina , Florence Dalenc , Philippe Aftimos , Filipa Lynce , Sami Diab , Javier Cortés , Joyce O'Shaughnessy , Véronique Diéras , Cristiano Ferrario , Peter Schmid , Lisa A Carey , Luca Gianni , Martine J Piccart , Sibylle Loibl , David M Goldenberg , Quan Hong , Martin S Olivo , Loretta M Itri , Hope S Rugo ; ASCENT Clinical Trial Investigators. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.N Engl J Med. 2021 Apr 22;384(16):1529-1541.
Please enable JavaScript in your browser to complete this form.